Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus
Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a recently emerged tickborne virus in east Asia with over 18,000 confirmed cases. With a high case fatality ratio, SFTSV has been designated a high priority pathogen by the WHO and the NIAID. Despite this, there are currently n...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/12/1403 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850059886063255552 |
|---|---|
| author | Philip Hicks Tomaz B. Manzoni Jonna B. Westover Raegan J. Petch Brianne Roper Brian B. Gowen Paul Bates |
| author_facet | Philip Hicks Tomaz B. Manzoni Jonna B. Westover Raegan J. Petch Brianne Roper Brian B. Gowen Paul Bates |
| author_sort | Philip Hicks |
| collection | DOAJ |
| description | Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a recently emerged tickborne virus in east Asia with over 18,000 confirmed cases. With a high case fatality ratio, SFTSV has been designated a high priority pathogen by the WHO and the NIAID. Despite this, there are currently no approved therapies or vaccines to treat or prevent SFTS. Vesicular stomatitis virus (VSV) represents an FDA-approved vaccine platform that has been considered for numerous viruses due to its low sero-prevalence in humans, ease in genetic manipulation, and promiscuity in incorporating foreign glycoproteins into its virions. Methods: In this study, we developed a recombinant VSV (rVSV) expressing the SFTSV glycoproteins Gn/Gc (rVSV-SFTSV) and assessed its safety, immunogenicity, and efficacy in C57BL/6, <i>Ifnar<sup>−/−</sup></i>, and AG129 mice. Results: We demonstrate that rVSV-SFTSV is safe when given to immunocompromised animals and is not neuropathogenic when injected intracranially into young immunocompetent mice. Immunization of wild type (C57BL/6) and <i>Ifnar<sup>−/−</sup></i> mice with rVSV-SFTSV resulted in high levels of neutralizing antibodies and protection in a lethal SFTSV challenge model. Additionally, passive transfer of sera from immunized <i>Ifnar<sup>−/−</sup></i> mice into naïve animals was protective when given pre- or post-exposure. Finally, we demonstrate that immunization with rVSV-SFTSV cross protects AG129 mice against challenge with the closely related Heartland bandavirus despite negligible neutralizing titers to the virus. Conclusions: Taken together, these data suggest that rVSV-SFTSV is a promising vaccine candidate for SFTSV and Heartland bandavirus with a favorable safety profile. |
| format | Article |
| id | doaj-art-e19587ee72a844248a3a5f0119dc252f |
| institution | DOAJ |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-e19587ee72a844248a3a5f0119dc252f2025-08-20T02:50:44ZengMDPI AGVaccines2076-393X2024-12-011212140310.3390/vaccines12121403Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland BandavirusPhilip Hicks0Tomaz B. Manzoni1Jonna B. Westover2Raegan J. Petch3Brianne Roper4Brian B. Gowen5Paul Bates6Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT 84322, USADepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT 84322, USADepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USABackground: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a recently emerged tickborne virus in east Asia with over 18,000 confirmed cases. With a high case fatality ratio, SFTSV has been designated a high priority pathogen by the WHO and the NIAID. Despite this, there are currently no approved therapies or vaccines to treat or prevent SFTS. Vesicular stomatitis virus (VSV) represents an FDA-approved vaccine platform that has been considered for numerous viruses due to its low sero-prevalence in humans, ease in genetic manipulation, and promiscuity in incorporating foreign glycoproteins into its virions. Methods: In this study, we developed a recombinant VSV (rVSV) expressing the SFTSV glycoproteins Gn/Gc (rVSV-SFTSV) and assessed its safety, immunogenicity, and efficacy in C57BL/6, <i>Ifnar<sup>−/−</sup></i>, and AG129 mice. Results: We demonstrate that rVSV-SFTSV is safe when given to immunocompromised animals and is not neuropathogenic when injected intracranially into young immunocompetent mice. Immunization of wild type (C57BL/6) and <i>Ifnar<sup>−/−</sup></i> mice with rVSV-SFTSV resulted in high levels of neutralizing antibodies and protection in a lethal SFTSV challenge model. Additionally, passive transfer of sera from immunized <i>Ifnar<sup>−/−</sup></i> mice into naïve animals was protective when given pre- or post-exposure. Finally, we demonstrate that immunization with rVSV-SFTSV cross protects AG129 mice against challenge with the closely related Heartland bandavirus despite negligible neutralizing titers to the virus. Conclusions: Taken together, these data suggest that rVSV-SFTSV is a promising vaccine candidate for SFTSV and Heartland bandavirus with a favorable safety profile.https://www.mdpi.com/2076-393X/12/12/1403bandavirussevere fever with thrombocytopenia syndrome virusheartland virusheartland bandavirusDabie bandavirusvaccine |
| spellingShingle | Philip Hicks Tomaz B. Manzoni Jonna B. Westover Raegan J. Petch Brianne Roper Brian B. Gowen Paul Bates Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus Vaccines bandavirus severe fever with thrombocytopenia syndrome virus heartland virus heartland bandavirus Dabie bandavirus vaccine |
| title | Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus |
| title_full | Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus |
| title_fullStr | Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus |
| title_full_unstemmed | Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus |
| title_short | Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus |
| title_sort | safety immunogenicity and efficacy of a recombinant vesicular stomatitis virus vectored vaccine against severe fever with thrombocytopenia syndrome virus and heartland bandavirus |
| topic | bandavirus severe fever with thrombocytopenia syndrome virus heartland virus heartland bandavirus Dabie bandavirus vaccine |
| url | https://www.mdpi.com/2076-393X/12/12/1403 |
| work_keys_str_mv | AT philiphicks safetyimmunogenicityandefficacyofarecombinantvesicularstomatitisvirusvectoredvaccineagainstseverefeverwiththrombocytopeniasyndromevirusandheartlandbandavirus AT tomazbmanzoni safetyimmunogenicityandefficacyofarecombinantvesicularstomatitisvirusvectoredvaccineagainstseverefeverwiththrombocytopeniasyndromevirusandheartlandbandavirus AT jonnabwestover safetyimmunogenicityandefficacyofarecombinantvesicularstomatitisvirusvectoredvaccineagainstseverefeverwiththrombocytopeniasyndromevirusandheartlandbandavirus AT raeganjpetch safetyimmunogenicityandefficacyofarecombinantvesicularstomatitisvirusvectoredvaccineagainstseverefeverwiththrombocytopeniasyndromevirusandheartlandbandavirus AT brianneroper safetyimmunogenicityandefficacyofarecombinantvesicularstomatitisvirusvectoredvaccineagainstseverefeverwiththrombocytopeniasyndromevirusandheartlandbandavirus AT brianbgowen safetyimmunogenicityandefficacyofarecombinantvesicularstomatitisvirusvectoredvaccineagainstseverefeverwiththrombocytopeniasyndromevirusandheartlandbandavirus AT paulbates safetyimmunogenicityandefficacyofarecombinantvesicularstomatitisvirusvectoredvaccineagainstseverefeverwiththrombocytopeniasyndromevirusandheartlandbandavirus |